Capricor Therapeutics Q4 Results Miss Expectations, Stock Price Declines

LootboxPhobia · 2026-03-12T22:33:12+00:00

Capricor Therapeutics reported a Q4 loss per share of $0.62, missing expectations. The company's quarterly revenue was zero, compared to $11.1 million in the same period last year, with net losses expanding to $30.2 million. The biologics license application for Deramiocel is under FDA review, with a target approval date of August 2026. 2025 net losses reached $105 million, with operating expenses increasing year-over-year. Cash position stands at approximately $318 million, expected to support operations through 2027.

LootboxPhobia

2026-03-12 22:33:12

Abstract generation in progress

Investing.com – Capricor Therapeutics (NASDAQ:CAPR) announced a fourth-quarter loss of $0.62 per share, missing analysts’ expectations of a $0.51 loss per share. The biotech company’s revenue for the quarter was zero, compared to $11.1 million in the same period last year, due to the company fully recognizing milestone payments from its distribution agreement with Nippon Shinyaku at the end of 2024.

After-hours trading on Thursday saw the company’s stock drop 1.3%. The net loss for the quarter widened to approximately $30.2 million, compared to $7.1 million in Q4 2024. Operating expenses increased year-over-year from $18.8 million to $29.2 million, mainly driven by commercialization preparation activities.

Capricor CEO Linda Marbán stated, “As we enter 2026, Capricor has significant regulatory and clinical momentum. We are working to secure potential approval for Deramiocel to treat Duchenne muscular dystrophy.”

The company’s biologics license application for Deramiocel is under review by the FDA, with a PDUFA target action date of August 22, 2026. The pivotal HOPE-3 Phase 3 trial met its primary endpoint for upper limb function and a key secondary cardiac endpoint of left ventricular ejection fraction, both achieving statistical significance. Data presented at the 2026 MDA Clinical & Scientific Conference showed that cardiac MRI analysis indicated a significant reduction in myocardial fibrosis.

For the full year 2025, Capricor reported a net loss of approximately $105 million, or $2.26 per share, compared to a net loss of $40.5 million, or $1.15 per share, in 2024. Total operating expenses for 2025 were $108.1 million, up from $64.8 million in 2024.

As of December 31, 2025, the company’s cash position totaled approximately $318.1 million, benefiting from a net proceeds of $161.9 million from a public offering in December. Capricor expects this cash to support operations through 2027.

This article was translated with the assistance of artificial intelligence. For more information, please see our Terms of Use.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.